Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Real-time Estimate Cboe BZX Other stock markets 02:39:34 2026-02-06 pm EST			5-day change	1st Jan Change
166.08 ^USD	+1.79%		+0.79%	-2.48%

Feb. 03	Rigel Pharmaceuticals, Inc. Appoints Michael P. Miller to Its Board of Directors	CI
Jan. 30	ALX Oncology Holdings Inc. Announces New Data from a Phase 1b/2 Clinical Trial Evaluating the Company's Investigational CD47-Inhibitor Evorpacept in Combination with Jazz Pharmaceuticals' ZIIHERTU	CI

Transcript : Jazz Pharmaceuticals plc Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 11

Published on 01/13/2026 at 04:06 pm EST - Modified on 01/14/2026 at 12:20 pm EST

S&P Capital IQ

Presenter Speech
Jessica Fye (Analysts)

Great. Good afternoon, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we're continuing the 44th Annual Healthcare Conference today with

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Jazz Pharmaceuticals plc

Feb. 03	Rigel Pharmaceuticals, Inc. Appoints Michael P. Miller to Its Board of Directors	CI
Jan. 30	ALX Oncology Holdings Inc. Announces New Data from a Phase 1b/2 Clinical Trial Evaluating the Company's Investigational CD47-Inhibitor Evorpacept in Combination with Jazz Pharmaceuticals' ZIIHERTU	CI
Jan. 13	Jazz Pharmaceuticals plc Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 11:15 AM
Jan. 12	Jazz Pharmaceuticals plc - Expects to meet 2025 revenue guidance - SEC filing	RE
Jan. 12	Truist Raises Price Target on Jazz Pharmaceuticals to $230 From $220, Keeps Buy Rating	MT
Jan. 12	Boehringer Ingelheim Announces Clinical Collaboration with Jazz Pharmaceuticals to Advance Her2-Targeted Therapy in Breast Cancer	CI
Jan. 09	Jazz Pharmaceuticals plc - Special Call
Jan. 08	Jazz Pharmaceuticals Names Chief Business Officer	MT
Jan. 08	Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer, Effective January 1, 2026	CI
Jan. 08	RBC Trims Price Target on Jazz Pharmaceuticals to $191 From $194, Keeps Outperform Rating	MT
Jan. 06	Jazz Pharmaceuticals announce positive efficacy from Ziihera phase 3 trial	RE
Jan. 06	Zymeworks Inc. Announces Positive Efficacy and Safety Results from the Phase 3 HERIZON-GEA-01 Trial Evaluating Ziihera	CI
Dec. 17	What will change if the US reclassifies marijuana?	RE
Dec. 11	Jazz Pharmaceuticals Insider Sold Shares Worth $379,366, According to a Recent SEC Filing	MT
Dec. 10	This Is Decision Day
Dec. 10	Analyst recommendations: Abbvie, Biogen, PepsiCo, Eli Lilly, Netflix…
Dec. 09	Jazz Pharmaceuticals Insider Sold Shares Worth $797,783, According to a Recent SEC Filing	MT
Dec. 05	Jazz Pharmaceuticals plc to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex®? (Cannabidiol) Outcomes in Treatment-Resistant Epilepsies At the American Epilepsy Society 2025 Annual Meeting	CI
Dec. 02	Jazz Pharmaceuticals plc to Present Pivotal Phase 3 Results of Ziihera®? (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCOGastrointestinal Cancers Symposium	CI
Dec. 02	Jazz Pharmaceuticals plc Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 09:45 AM
Dec. 02	Jazz Pharmaceuticals Insider Sold Shares Worth $13,780,337, According to a Recent SEC Filing	MT
Nov. 27	Stockholm Bullets – Arise Soars on Takeover Bid	FW
Nov. 27	Saniona Reports Operating Profit of SEK 360 Million	FW
Nov. 24	Jazz Pharmaceuticals Insider Sold Shares Worth $607,127, According to a Recent SEC Filing	MT
Nov. 24	Jazz Gains From Ziihera Data, Upside Seen as Priced In, UBS Says	MT